Introduction Natural autoantibodies are part of the normal human immunoglobulin repertoire. These antibodies react to self-antigens, are usually polyreactive with relatively low affinity, and typically are of the IgM isotype. Natural IgMs in mice that stimulated remyelination in central nervous system (CNS) demyelinating disease all shared the characteristics of binding to the surface of live oligodendrocytes and myelinated tracts in living slices of CNS tissue. Methods A screen for human IgMs with similar character resulted in two human natural antibodies, which when injected peripherally into animal models of demyelination induced remyelination. A recombinant human IgM (rHIgM22) that also promoted remyelination in vivo was constructed. Results Very small doses of this IgM are required for the promotion of remyelination (EC50 is 460 ng per 20-g mouse).
Introduction
Naturally occurring autoantibodies are part of our human immunoglobulin repertoire [1] . Natural autoreactive (NA) monoclonal IgM antibodies can promote central nervous system (CNS) protection and repair. These repairpromoting IgMs have characteristics of classic NA antibodies. They are, for example, generally of the IgM isotype, are encoded by germline genes with few somatic mutations, and are polyreactive with low affinity with a range of structurally unrelated, self and nonself antigens, specifically cytoskeleton, nuclear proteins, and DNA [2] . Naturally occurring autoantibodies react to self-antigens, whereas conventional antibodies react to exogenous antigens. Compared with conventional antibodies, natural autoantibodies are of relatively low affinity. They are derived from our germline immunoglobulin genes but can also contain somatic mutations. They are frequently polyreactive. More frequently, naturally occurring autoantibodies are IgMs rather than IgGs and usually are physiologic unlike conventional antibodies, which are blocking or pathologic. ation begins at 21 days postinfection and plateaus at 90 days postinfection. From this point on, the disease involves primarily neuronal injury and the progressive dropout of large caliber axons, accounting for progressive clinical deficits [4] . This provides an ideal model in which to screen drugs designed to promote remyelination as well as to protect axons (Fig. 1) .
Our discovery of natural antibodies for CNS repair was serendipitous. To test the hypothesis of virusinduced autoimmunity and molecular mimicry, mice with TMEV-induced demyelination were also immunized with myelin. However, when mice were immunized with CNS antigens months after TMEV infection, rather than more extensive demyelination, significant spinal cord remyelination was observed [5] . Classical passive-transfer studies were performed in which antisera or purified immunoglobulins from uninfected mice immunized with myelin antigens were transferred into mice with extensive TMEV-mediated spinal cord demyelination [6] . Mice that received hyperimmune sera or immunoglobulin directed against myelin demonstrated extensive remyelination after 5 weeks compared with mice that received control antisera.
To determine whether monoclonal antibodies (mAbs) could promote remyelination, we generated a panel of monoclonal clones against spinal cord antigens. Supernatants from groups of ten spinal cord homogenate-binding clones were tested in TMEV-infected mice for the ability to promote remyelination. If a group of supernatants was positive, the individual clones were then tested for remyelination. The first remyelination-promoting mAb identified was spinal cord homogenate 94.03 (SCH 94.03) [7] . This IgM, when injected peritoneally, induced almost complete remyelination in 30% of spinal cord lesions in TMEV-infected mice. This is in contrast to control monoclonal clones, where less than 5% of spinal cord lesions were remyelinated. In characterizing SCH94.03, we found it bound to the surface of living oligodendrocytes. Several well-characterized mouse IgMs, A2B5, O1, O4, HNK-1, which bound to glycolipids on the surface of live oligodendrocytes and are used to characterize the oligodendrocyte lineage, were tested and also promoted remyelination [8] . These IgMs had relatively conserved germline sequences. We hypothesized that IgM-mediated remyelination required recognition of oligodendrocyte plasma membrane lipids.
Identification of Human Antibodies that Promote Remyelination
Based on these observations, we asked whether in the human population natural antibodies were present that bound to oligodendrocytes and could promote remyelination. We used a novel strategy to identify potential therapeutic human molecules by screening for autoreactive human mAbs from the sera of individuals that carry the mAbs in high concentration [9] . Searching through more than 140,000 samples archived more than 50 years in the Mayo Clinic serum bank, we sought samples from patients with monoclonal gammopathies; these diseases result in an immortalized B cell clone and a high level of serum monoclonal protein (Fig. 2) . Specifically, samples from patients with multiple myeloma, Waldenstrom's syndrome, and monoclonal gammopathy of unknown significance were identified. We screened for antibody binding to myelin in slices of live mouse CNS and to the surface of oligodendrocytes in culture without regard for antigen. Six of 52 serum-derived human IgMs (sHIgM) and 0 of 50 serum-derived human IgGs bound in these assays. The histories of the patients synthesizing positive mAbs were From this point on, the disease involves primarily progressive neuronal injury where the dropout of large caliber axons accounts for increasing clinical deficits. The more widely used model of human MS, EAE, is primarily autoimmunemediated, and therefore, a large number of immune-modulating reagents improve clinical disease. In the TMEV model, immunosuppression increases virus load as immune surveillance of the CNS is reduced. TMEV-mediated disease would likely improve with effective antiviral therapy. Such options are limited in humans. Remyelinationpromoting IgMs are the only identified reagents that promote CNS repair without modulating the immune system or altering viral load in this model examined to ensure that there were no neurologic-or antibody-associated pathologies. Positive mAbs were then tested for the ability to modulate in vivo demyelinating disease. Two human IgMs (sHIgM22 and sHIgM46) promoted significant remyelination in TMEV-infected mice (Fig. 3) . We also tested IVIG and polyclonal human IgM for the ability to promote remyelination in the TMEV model. Both were effective, but polyclonal IgM and the two human monoclonal IgMs were superior. IVIG may be effective in the TMEV model by modulating the immune response, whereas the IgMs may act directly upon the cells of the nervous system [9] . The recognition of the surface of appropriate tissues or cells appears to be an important defining characteristic of therapeutic IgMs. The IgMs Fig. 2 Alternative approach to the identification and production of therapeutic human mAbs. A critical need exists for toxicity testing early in drug development. Safety issues are the most common cause of drug candidate attrition from the pipeline and the marketplace. This alternative approach to identifying antibody-based drugs starts with a screen from the hundreds of thousands of samples collected over 45 years in the Mayo Clinic serum bank for those patients with a monoclonal spike in the sera. These are typically patients with lymphoproliferative disorders where a B cell expansion results in high levels of monoclonal protein in their circulation. The strength of this approach to human mAb identification is that the candidate antibodies are, in a sense, tested for toxicity by the patient who carries them. Samples from patients with antibody-based disease are excluded. However, mAbs with characteristics of interest are identified without regard to antigen or mechanism of action. Antigen discovery or a reasonable understanding of the mechanism of action is necessary to translate reagents such as mAbs to a marketable drug [8, 10] .
Using oligodendrocytes isolated from human tissue from patients undergoing temporal lobectomy for epilepsy, we were able to demonstrate that both human IgMs bound to the surface of human oligodendrocytes in vitro, providing evidence that these IgMs may be effective in promoting remyelination in human patients. This method of identifying mAbs with biologic efficacy is very different from the traditional methodology used by the pharmaceutical industry [11] . Each patient has carried high concentrations of monoclonal Ig in their blood for many years without neurologic disease. Each IgM isolated, in a certain sense, already has been tested for toxicology by the individual that carried the antibody.
Development of a Recombinant Expression Vector for Human IgMs
To definitively prove that IgM and no other serum factors promoted remyelination, we developed a recombinant version of sHIgM22. We developed an expression vector that incorporated a methotrexate amplification system capable of receiving any human heavy chain sequence and light chain sequence to generate large quantities of pure recombinant mAb. rHIgM22 promoted myelin repair in the TMEV-induced model of MS equal to or better than the serum-derived form. rHIgM22 binds to the surface of live oligodendrocytes and myelin and promotes CNS remyelination in virus [12] and toxin-induced models of MS [13] . Spinal cord remyelination is induced after a single low dose (25 μg/kg) of rHIgM22 [14] . It is remarkable that one peripheral intraperitoneal injection of a short-lived molecule (15-hour half-life in the mouse sera) promotes maximal tissue repair within 5 weeks in a model of MS that normally presents with little spontaneous repair. The properties of rHIgM22 are similar to that of a targetable growth factor.
To determine whether noninvasive imaging could be used to measure IgM-mediated repair of the CNS, we measured the total volume of spinal lesions by magnetic resonance imaging (MRI) before treatment with rHIgM22 and 5 weeks after treatment. The entire mouse spinal cord was scanned by MRI, lesions were represented by voxels, and the total resulting pixels were calculated in three dimensions in both T1-and T2-weighted MRI scans [15] . Comparing initial spinal cord lesion load with that seen 5 weeks later, we found that mice receiving control saline showed slightly increasing lesion volumes. In contrast, mice treated with rHIgM22 showed a remarkable decrease in lesion volume load in the spinal cord. Again, these results were obtained after a single dose of the IgM, and nearly every mouse responded with decreased lesion size. We correlated spinal cord areas of reduction of MRI signal with histology in 1-μm thick araldite-embedded sections of the spinal cord. We discovered there was a precise correlation between areas of reduction of MRI signal and areas of remyelination.
We tested whether rHIgM22 promoted spinal cord remyelination by altering an aspect of the immune response. We measured no change in immune function in TMEV-infected mice or in mice with experimental autoimmune encephalomyelitis (EAE) induced by adoptive transfer of myelin basic protein-specific T cells [16] . Another possibility was that rHIgM22 reduced the level of virus in TMEV-infected mice, allowing normal repair to proceed. Immunosuppressive treatment of TMEV-infected mice leads to remyelination but also to an increase in virus replication in the CNS [17] . We found that a 500-μg dose of rHIgM22 given to chronically TMEV-infected mice did not reduce CNS virus load as measured by Northern blot or immunocytochemistry [16] . Therefore, rHIgM22 promotes remyelination without affecting the virus replication.
The development of rHIgM22 is at the point of GMP commercial production, purification, and animal toxicology. Gram quantities of GMP-grade rHIgM22 have been purified for formal toxicology and a potential phase 1 clinical trial for safety in 2010. The studies in this disease model suggest that very little rHIgM22 will be required to modulate human disease. A mouse weighing 20 g responding to a 500-ng dose corresponds to a 2-mg dose in an adult human weighing 50 or 70 kg.
IgMs Can Enter the CNS After Peripheral Administration
It has been generally accepted that IgMs with a molecular weight of close to 1 million are too large to cross the blood-brain barrier (BBB) and enter the CNS [18] . However, evidence is accumulating that some IgMs can cross the BBB. A study by our laboratory [19] examined the tissue localization of a mouse monoclonal IgM shown to promote remyelination, SCH94.03.
35 S-methionine labeled SCH94.03 was administered intraperitoneally to TMEV-infected and uninfected SJL mice. In infected mice, radiolabel accumulated in the brain, spinal cord, heart, lung, and muscle, and plateaued by 24 hours. In uninfected mice, radiolabel accumulated at similar levels but required 7 days to plateau. It was calculated that 0.4% of the administered 35 S counts accumulated in the brain and spinal cord of both uninfected and TMEV-infected mice. We performed an MRI-based study that used a 7-T magnet to localize rHIgM22 in TMEV-infected mice [15] . rHIgM22 entry into the CNS and accumulation in lesions were demonstrated prominently by MRI. In mice that were not infected with virus or did not have demyelination, rHIgM22 did not accumulate in the CNS [15] . A control human IgM that does not bind to myelin or oligodendrocytes did not accumulate in CNS lesions.
Other independent investigators have also demonstrated that certain human IgMs can cross the BBB [20] . The ability of two human anti-beta amyloid (Aβ) IgMs to cross the BBB in normal and SAMP8 mice (a model of Alzheimer's disease [AD]) was compared.
125 I labeled human IgMs were injected intravenously. One anti-Aβ IgM (L11.3) accumulated in the brain of normal and diseased mice 2 hours later. The L11.3 anti-Aβ IgM reversed cognitive impairment in the AD mice whether the IgM was delivered by intracerebral injection or intravenously. It is well established that anti-Aβ antibodies delivered to the brain of mice that overexpress Aβ can reverse histologic and cognitive impairment; these antibodies form the foundation of Aβ immunization strategies in human trials.
These data support the concept that some IgMs can cross the BBB with low efficiency, enter the CNS and accumulate within injured regions of the CNS. It should be stressed that very little drug is required in the CNS to produce a therapeutic effect. Only 0.02% of a peripheral dose of morphine enters the brain, yet this is sufficient for analgesia. For most CNS therapeutics on the market, less than 0.2% of a peripheral dose enters the CNS.
Mechanism of Action: Clustering of Specific Membrane Domains
We propose that the mechanism of action of IgMs is through lipid microdomain signaling. The large pentameric structure of IgM can easily cross-link antigens on the cell surface to bring together molecules that normally do not interact into a signaling complex. In fact, the pentameric structure of rHIgM22 is necessary for in vivo remyelination. Although remyelination-promoting IgMs bind to the surface of oligodendrocytes, not all human IgMs that bind to oligodendrocytes promote remyelination. Therefore, IgM-mediated repair requires binding to specific antigens on the oligodendrocyte membrane. All of the IgMs that promote remyelination induce a transient calcium influx in glial cells [21] . Transient elevation of Ca ++ in cells is associated with cell survival, whereas persistent elevation of Ca ++ is associated with cell death. Disruption of the lipid microdomain by the detergent B-methyl cyclodextrin prevents Ca ++ signaling [22] . The exact antigen bound by rHIgM22 on myelin is not required to move forward to FDA approval, if reasonable data exist supporting an in vivo mechanism of action. We have recently discovered that rHIgM22 does not bind to live CNS tissue slices from glycolipid knockout mice. Myelinated tracts in mice lacking the enzymes cerebroside sulfotransferase or cerebroside galactosyltransferase, and therefore lacking sulfatide or galactosylcerebroside, are not recognized by rHIgM22. However, rHIgM22 does not bind to other sulfatide-expressing tissues such as peripheral nervous system myelin and Schwann cells. These data support the hypothesis that rHIgM22 binding depends upon sulfated antigens present exclusively in the CNS.
There are currently no effective treatments to prevent or reverse deficits in MS. Available drugs target immune aspects of the disease and have no effect on the chronic, progressive form of the disease. rHIgM22 will be the first therapeutic designed to enhance repair in an MS lesion by targeting cells of the brain and spinal cord. If successful, this will increase interest in natural antibodies as safe, lowdose therapeutic reagents.
